PharmTech News

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

In testifying before Congress on FDA regulation of long-awaited biosimilars, Janet Woodcock emphasized the importance of ensuring that the evaluation of new therapies is based on sound science.

FDA Promotes Its Scientific Mission

Intuniv (guanfacine hydrochloride prolonged-release tablets) is the first selective alpha-2A adrenergic receptor agonist licensed for the treatment of attention deficit hyperactivity disorder in Europe.

Shire’s Once-Daily ADHD Tablets Approved in Europe

The White House nominates Robert Califf to head FDA, but will he be confirmed?

Confirmation for Califf?

President Obama will nominate Rob Califf, current deputy commissioner for medical products and tobacco, as FDA commissioner.

Rob Califf Named to Fill FDA Commissioner Post

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

According to AstraZeneca, the purchase of the biologics bulk plant will double the company's biologics manufacturing capacity in the US.

AstraZeneca Buys Amgen's Biologics Manufacturing Facility

The partners will collaborate on a project to capture and integrate clinical trial data metrics on investigational cancer medications.

AstraZeneca and the University of Manchester Team Up on Bioinformatics Venture

Pfizer closes the acquisition of Hospira, adding sterile injectables business to portfolio.

Pfizer Completes Acquisition of Hospira

The platform, developed by Vectron Biosolutions, will be used for BI’s in-house pipeline and for its outsourcing clients.

Boehringer Ingelheim Licenses Expression Technology Platform

Under the terms of the agreement, Sartorius Stedim Biotech will manufacture membrane adsorber technologies for GE, which will be marketed as part of GE’s ReadyToProcess product offerings.

Sartorius Stedim Biotech to Supply Membrane Adsorber Technologies to GE Healthcare

Growth is said to be driven by the deeper penetration of biosimilars in developed and emerging markets as a result of clearer regulatory pathways.

Top News